The peripheral L-arginine-nitric oxide-cyclic GMP pathway and ATP-sensitive K+ channels are involved in the antinociceptive effect of crotalphine on neuropathic pain in rats


Autoria(s): Gutierrez, Vanessa Pacciari; Zambelli, Vanessa Olzon; Picolo, Gisele; Chacur, Marucia; Sampaio, Sandra C.; Brigatte, Patrícia; Konno, Katsuhiro; Cury, Yara
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

24/10/2013

24/10/2013

2012

Resumo

Crotalphine, a 14 amino acid peptide first isolated from the venom of the South American rattlesnake Crotalus durissus terrificus, induces a peripheral long-lasting and opioid receptor-mediated antinociceptive effect in a rat model of neuropathic pain induced by chronic constriction of the sciatic nerve. In the present study, we further characterized the molecular mechanisms involved in this effect, determining the type of opioid receptor responsible for this effect and the involvement of the nitric oxide-cyclic GMP pathway and of K+ channels. Crotalphine (0.2 or 5 mu g/kg, orally; 0.0006 mu g/paw), administered on day 14 after nerve constriction, inhibited mechanical hyperalgesia and low-threshold mechanical allodynia. The effect of the peptide was antagonized by intraplantar administration of naltrindole, an antagonist of delta-opioid receptors, and partially reversed by norbinaltorphimine, an antagonist of kappa-opioid receptors. The effect of crotalphine was also blocked by 7-nitroindazole, an inhibitor of the neuronal nitric oxide synthase; by 1H-(1,2,4) oxadiazolo[4,3-a]quinoxaline-1-one, an inhibitor of guanylate cyclase activation; and by glibenclamide, an ATP-sensitive K+ channel blocker. The results suggest that peripheral delta-opioid and kappa-opioid receptors, the nitric oxide-cyclic GMP pathway, and ATP-sensitive K+ channels are involved in the antinociceptive effect of crotalphine. The present data point to the therapeutic potential of this peptide for the treatment of chronic neuropathic pain. Behavioural Pharmacology 23:14-24 (C) 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brazil (FAPESP) [1998/14307-9, 2002/04918-8, 2007/02478-4, 2007/00135-2, 2007/03404-4]

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Brazil

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) (FAPESP)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)/FAPESP [2008/57898-0]

Financeira de Estudos e Projetos (FINEP) [2050/04]

Financeira de Estudos e Projetos (FINEP)

Identificador

BEHAVIOURAL PHARMACOLOGY, PHILADELPHIA, v. 23, n. 1, supl. 1, Part 3, pp. 14-24, FEB, 2012

0955-8810

http://www.producao.usp.br/handle/BDPI/36028

10.1097/FBP.0b013e32834eafbc

http://dx.doi.org/10.1097/FBP.0b013e32834eafbc

Idioma(s)

eng

Publicador

LIPPINCOTT WILLIAMS & WILKINS

PHILADELPHIA

Relação

BEHAVIOURAL PHARMACOLOGY

Direitos

restrictedAccess

Copyright LIPPINCOTT WILLIAMS & WILKINS

Palavras-Chave #ANTINOCICEPTION #ATP-SENSITIVE POTASSIUM CHANNELS #CROTALPHINE #NITRIC OXIDE-CYCLIC GMP PATHWAY #OPIOID RECEPTORS #RAT #DELTA-OPIOID RECEPTORS #CROTALUS-DURISSUS-TERRIFICUS #HIV-1 ENVELOPE GLYCOPROTEIN #DORSAL-ROOT GANGLIA #SPINAL-CORD #SNAKE-VENOM #PROINFLAMMATORY CYTOKINES #POTASSIUM CHANNELS #BLOOD-PRESSURE #AGONIST #BEHAVIORAL SCIENCES #NEUROSCIENCES #PHARMACOLOGY & PHARMACY
Tipo

article

original article

publishedVersion